Home » Lupin Pushes Into Generic Opportunities in the U.S. Pharmaceutical Market

Lupin Pushes Into Generic Opportunities in the U.S. Pharmaceutical Market

February 1, 2013

The U.S. was a key contributor to the overall performance on the back of a strong flu season and the Tricor launch for pharma company Lupin, says Nomura Equity Research.
moneylife

05Aug
Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management
10Aug
Is Biosimilars Regulation Taking a Major Turn?: The Latest Must-Know Developments, Including BsUFA III
12Aug
On-Site Inspections: They’re Back — But When, Where and How
16Aug
Using AI for CAPA and Root Cause Investigation
28Sep
4th Annual WCG MCC Clinical Trial Risk & Performance Management Collaborative vSummit
12Oct
Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

Lupin Pushes Into Generic Opportunities in the U.S. Pharmaceutical Market

Upcoming Events

Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

Is Biosimilars Regulation Taking a Major Turn?: The Latest Must-Know Developments, Including BsUFA III

On-Site Inspections: They’re Back — But When, Where and How

Using AI for CAPA and Root Cause Investigation

4th Annual WCG MCC Clinical Trial Risk & Performance Management Collaborative vSummit

Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

FDA Yanks Notice of PDUFA Fee Increase for Fiscal 2022

RealView Imaging’s Medical Holography System Cleared

European Commission Agrees to Buy Up To 200 Million Doses of Novavax’s COVID-19 Vaccine

FDA Designates VenoValve a Breakthrough Device

The Revised ICH E8: A Guide to New Clinical Trial Requirements